ID   SJ-GBM2
AC   CVCL_M141
SY   SJ-GBM-2; SJGBM2; SJ-G2; SJG2
DR   BTO; BTO:0006332
DR   cancercelllines; CVCL_M141
DR   IARC_TP53; 24985
DR   Wikidata; Q54953524
RX   CelloPub=CLPUB00738;
RX   PubMed=7634381;
RX   PubMed=9220028;
RX   PubMed=9802058;
RX   PubMed=10402232;
RX   PubMed=10933967;
RX   PubMed=11306486;
RX   PubMed=20922763;
WW   https://www.cccells.org/PDF_Files/Brain/SJ-GBM2.pdf
WW   https://www.cccells.org/tables/Brain.php
WW   http://www.pptpinvitro.org/cell_lines_panel.php
CC   Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 29 hours (PubMed=20922763).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (CelloPub=CLPUB00738; PubMed=9802058).
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
ST   Source(s): COG; PubMed=20922763
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11,12
ST   D16S539: 11
ST   D18S51: 16,17
ST   D19S433: 12,14
ST   D2S1338: 17,24
ST   D3S1358: 15
ST   D5S818: 12
ST   D7S820: 12
ST   D8S1179: 8,12
ST   FGA: 24
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 17,18
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   6Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 05-10-23; Version: 15
//
RX   CelloPub=CLPUB00738;
RA   Nitiss K.C.;
RT   "Oncogenic changes and induction of differentiation in pediatric
RT   astrocytic cell lines.";
RL   Thesis PhD (1997), University of Southern California Los Angeles, United States.
//
RX   PubMed=7634381; DOI=10.1007/BF00686188;
RA   Houghton P.J., Cheshire P.J., Hallman J.D. II, Lutz L., Friedman H.S.,
RA   Danks M.K., Houghton J.A.;
RT   "Efficacy of topoisomerase I inhibitors, topotecan and irinotecan,
RT   administered at low dose levels in protracted schedules to mice
RT   bearing xenografts of human tumors.";
RL   Cancer Chemother. Pharmacol. 36:393-403(1995).
//
RX   PubMed=9220028; DOI=10.1016/S0303-7207(97)00080-4;
RA   Sharif T.R., Luo W., Sharif M.;
RT   "Functional expression of bombesin receptor in most adult and
RT   pediatric human glioblastoma cell lines; role in mitogenesis and in
RT   stimulating the mitogen-activated protein kinase pathway.";
RL   Mol. Cell. Endocrinol. 130:119-130(1997).
//
RX   PubMed=9802058;
RA   McPake C.R., Tillman D.M., Poquette C.A., George E.O., Houghton J.A.,
RA   Harris L.C.;
RT   "Bax is an important determinant of chemosensitivity in pediatric
RT   tumor cell lines independent of Bcl-2 expression and p53 status.";
RL   Oncol. Res. 10:235-244(1998).
//
RX   PubMed=10402232; DOI=10.3892/ijo.15.2.237;
RA   Sharif T.R., Sharif M.;
RT   "Overexpression of protein kinase C epsilon in astroglial brain tumor
RT   derived cell lines and primary tumor samples.";
RL   Int. J. Oncol. 15:237-243(1999).
//
RX   PubMed=10933967; DOI=10.1006/mthe.2000.0064;
RA   Pawlik C.A., Iyengar R.V., Krull E.J., Mason S.E., Khanna R.,
RA   Harris L.C., Potter P.M., Danks M.K., Guichard S.M.;
RT   "Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated
RT   overexpression of a rabbit carboxylesterase to sensitize neuroblastoma
RT   cells to CPT-11.";
RL   Mol. Ther. 1:457-463(2000).
//
RX   PubMed=11306486;
RA   Iyengar R.V., Pawlik C.A., Krull E.J., Phelps D.A., Burger R.A.,
RA   Harris L.C., Potter P.M., Danks M.K.;
RT   "Use of a modified ornithine decarboxylase promoter to achieve
RT   efficient c-MYC- or N-MYC-regulated protein expression.";
RL   Cancer Res. 61:3045-3052(2001).
//
RX   PubMed=20922763; DOI=10.1002/pbc.22801;
RA   Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J.,
RA   Reynolds C.P.;
RT   "National Cancer Institute pediatric preclinical testing program:
RT   model description for in vitro cytotoxicity testing.";
RL   Pediatr. Blood Cancer 56:239-249(2011).
//